Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Starts China Arm of Global RET Inhibitor Phase I Trial

publication date: Aug 13, 2019

CStone, a Suzhou biopharma, has dosed the first patient in the China arm of a global Phase I registrational study of BLU-667, a RET-inhibitor, in patients with various solid tumor cancers. One year ago, CStone in-licensed greater China rights to BLU-667 as part of a $386 million deal for three Blueprint oncology candidates. Blueprint has already started the global Phase I ARROW trial, which will evaluate the overall response rate, duration of response, pharmacokinetics, pharmacodynamics and safety of BLU-667 in NSCLC and other cancers. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.